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ABSTRACT: Mimicry of the binding interface of antibody−antigen interactions using
peptide-based modulators (i.e., epitope mimics) has promising applications for vaccine
design. These epitope mimics can be synthesized in a streamlined and straightforward
fashion, thereby allowing for high-throughput analysis. The design of epitope mimics is
highly inﬂuenced by their spatial conﬁguration and structural conformation. It is widely
assumed that for proper mimicry suﬃcient conformational constraints have to be
implemented. This paper describes the synthesis of bromide derivatives functionalized
with a ﬂexible TEG linker equipped with a thiol-moiety that could be used to support
cyclic or linear peptides. The cyclic and linear epitope mimics were covalently
conjugated via the free thiol-moiety on maleimide-activated plate surfaces. The resulting
covalent, uniform, and oriented coated surface of cyclic or linear epitope mimics were
subjected to an ELISA to investigate the eﬀect of peptide cyclization with respect to
mimicry of an antigen−antibody interaction of the HCV E2 glycoprotein. To the best of
our knowledge, the beneﬁt of cyclized peptides over linear peptides has been clearly
demonstrated here for the ﬁrst time. Cyclic epitope mimics, and not the linear epitope mimics, demonstrated speciﬁcity toward
their monoclonal antibodies HC84.1 and V3.2, respectively. The described strategy for the construction of epitope mimics shows
potential for high-throughput screening of key binding residues by simply changing the amino acid sequences within synthetic
peptides. In this way, leucine-438 has been identiﬁed as a key binding residue for binding monoclonal antibody V3.2.
■ INTRODUCTION
Hepatitis C Virus (HCV) poses a global threat and is estimated
to have infected over 3% of the world’s population.1 So far, its
high mutation rate and intrinsic immune evasive strategies have
hampered development of therapeutic and prophylactic
vaccines. Despite this and the availability of novel antivirals,2
there is an urgent need for the development of HCV vaccines,3
since drugs do not prevent reinfection4 and their treatment is
expensive.3 The potential of these possible future vaccines is
underlined by the existence of antibodies capable of preventing
viral infection (i.e., Neutralizing Antibodies (NAbs)).5
Evidently, the HCV E2 envelope glycoprotein is of major
importance for development of HCV vaccines,6 as it is involved
in viral attachment and entry, and is therefore an accessible
target located on the surface of the virion. However, generating
NAbs against this glycoprotein is not straightforward as it
contains highly variable immunogenic domains. Antibodies
against these regions tend to be strain-speciﬁc and unable to
prevent infection by a diﬀerent strain of HCV. These variable
epitopes serve as decoys to distract the immune system. In
addition, HCV E2 contains 11 N-linked glycans that can shield
certain epitopes, thereby preventing binding of antibodies.7
Nevertheless, numerous NAbs have been isolated from patient
sera that are able to inhibit infection by a broad range of HCV
isolates. Most of these broadly neutralizing antibodies bind to
conserved, discontinuous regions within the HCV E2
glycoprotein and block its interaction with the CD81 receptor.8
These regions are designated as broadly neutralizing epito-
pes.5,9−11 The availability of structural information on these
HCV E2 neutralizing epitope−antibody interactions might be
crucial for future vaccine design.5,10,12,13
A decade ago we introduced a chemical biology perspective
for designing synthetic vaccines by describing a strategy for
mimicry of discontinuous protective epitopes using a synthetic
scaﬀold for obtaining a ‘PEPTAC’ molecular construct, which
acted as a synthetic vaccine and protected mice against
infection with B. pertussis.14 Although this was a very promising
result, we think in order to further improve chances for
ultimately a successful synthetic HCV vaccine, we have to
mimic neutralizing epitopes present in E2 as closely as possible
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and ligate them on a diversity of suitable scaﬀold
molecules.15−17
The required scaﬀold molecule should mimic the structural
integrity that is normally provided for by the majority of a
protein (Figure 1). Thus, the resulting epitope containing
protein mimic will only present the essential epitope(s) and will
not contain any shielding or immunogenic decoy domains.
Consequently these protein mimics have the potential to lead
to synthetic and more eﬃcient vaccines.18,19
Conformational constraints are probably very important in
the design of epitope mimics, since they can induce or enforce
conformations of epitopes as they are present in the native
protein.15 Many epitopes comprise looplike structures, and
mimicry of looplike peptide sequences is best achieved by
cyclization. Furthermore, introduction of conformational
constraints by cyclization has been found to improve rigidity,
stability, bioavailability, and biological activity of peptide-based
therapeutics.14,17 Therefore, constrained peptides are preferred
in the design of adequate and eﬀective epitope mimics.20−25
However, to the best of our knowledge, this favorable eﬀect on
epitope mimicry by the introduction of conformational
constraints by cyclization has not been rigorously investigated
so far.
The cornerstone of studying antigen−antibody interactions
and the identiﬁcation of promising neutralizing epitopes is the
enzyme-linked immunosorbent assay (ELISA). With respect to
this, novel isolated NAbs, obtained from immunization studies
or patients, are tested by ELISA to verify binding.9,26,27 Key
binding residues of antigen−antibody interactions are identiﬁed
(i.e., epitope mapping) using mutagenesis studies, in which
ELISA is used to assess the altered binding aﬃnity of antibodies
toward diﬀerent mutants.9,28 Conventional ELISA involves
noncovalent adsorption of antigen(s) on polystyrene plates,
which likely results in a heterogeneous surface of diﬀerently
adsorbed antigen molecules. Thus, these will probably interact
with diﬀerent aﬃnities with antibodies.29 In addition,
adsorption of antigens on polystyrene plates could potentially
perturb the structure of the antigen, thereby also inﬂuencing
antibody binding. Gori et al. have shown the importance of
accurate control of covalent immobilization and generating a
uniform and oriented surface for proper gauging of antigen−
antibody interactions using peptide sequences.30
In this research we show the importance of cyclization of
peptides as a conformational constraint for eﬀective mimicry of
neutralizing epitopes from HCV E2. To this end, more ﬂexible,
linear peptides were compared with their constrained, cyclic
counterparts. These peptide constructs were obtained via
benzylic bromide derivatives equipped with a tetraethylene
glycol (TEG) spacer containing a trityl-protected thiol-moiety
(7 and 8, respectively). After liberation of the thiol moiety,
instead of random noncovalent adsorption, a covalent coating
of epitope mimics on polystyrene plates was obtained using
commercially available Pierce maleimide activated 96-well
plates (Figure 2).
The availability of a human/mouse antibody variant of the
broadly neutralizing human monoclonal antibody (mAb)
HC84.1,9 as well as weakly neutralizing mouse antibody V3.2
(to be published), enabled us to evaluate our epitope mimics
using ELISA and the impact of peptide cyclization for eﬀective
mimicry.
■ RESULTS AND DISCUSSION
Synthesis of the Peptide Cyclization and Linear Linker
with a Maleimide Reactive Tetraethylene Glycol (TEG)
Spacer. Recently, we introduced a bisbromobenzyl azide
derivative for cyclization of dicysteine containing peptides and
subsequent Cu-catalyzed azide−alkyne cyclo-addition to alkyne
containing scaﬀold molecules.14,17 Here a related bisbromo-
benzyl derivative was required, having instead of an azide
functionality a TEG moiety for improved water solubility and a
(protected) thiol group for reaction with maleimide moieties
present on the surface of an ELISA plate.31
Thus, TEG 1 was monotosylated to tosylate 2 (61%)
followed by substitution using crude trityl-thiol 3 leading to
trityl-TEG-sulﬁde 4 (quant.). Next, the cyclization linker moiety
was introduced in a reaction with 1,3,5-tris(bromomethyl)-
benzene 5 and trityl protected cyclization linker 7 was obtained
in a moderate yield (33%) (Scheme 1). Similarly, trityl-TEG-
sulﬁde 4 was reacted with 1,3-bis(bromomethyl)benzene 6, to
provide trityl protected linear linker 8 also in a moderate yield
(43%). Di- and trisubstituted products were observed during
the reaction of cyclic linker 7 and linear linker 8, which at least
partially explained the lower yields of the mono substituted
products. The availability of both scaﬀolds supporting cyclized
or linear peptide constructs was essential for a rigorous
evaluation of the constraining eﬀects by peptide cyclization.
Alkylation of Cysteine Containing Peptides with
Linkers 7 or 8. The required mono- or dicysteine containing
peptides were obtained by solid phase peptide synthesis. Their
amino acid sequences originated from Epitope II present in
HCV E2 glycoprotein (N434 TGWLAGLFYQHK446; residues
Figure 1. Epitope mimicry, in which essential peptide loops of a
discontinuous epitope are ligated on a molecular scaﬀold.
Figure 2. Chemoselective approach for covalent immobilization of
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in bold are highly conserved across genotypes).9,10,32,33 Epitope
II is a neutralizing immunogenic domain recognized by NAb
HC84.1 and weakly by NAb V3.2 (to be published). Epitopes
of mAb HC84.1 and V3.2 have been mapped to HCV E2
residues 439 to 4469,10 and residues 435 to 442 (to be
published), respectively. The available sequence information of
the diﬀerent HCV genotypes/strains allowed for the
optimization of epitope II toward consensus sequences
corresponding to residues 436 to 448 and 430 to 444 of
peptides shown in Table 1, which cover multiple genotypes of
HCV.
Peptides 9 (cp), 11 (cp), 13 (cp), and 14 (cp) served as
cyclization precursor (cp) peptides for the preparation of the
cyclic peptide constructs 15, 17, 19, and 20, respectively, and
were synthesized with a cysteine residue at both N- and C-
termini. Linear precursor (lp) peptides 10 (lp) and 12 (lp)
containing one cysteine residue were synthesized to prepare the
linear peptide constructs 16 and 18. In addition, peptide 14
(cp) was designed with a scrambled amino acid sequence and
synthesized for the preparation of cyclic peptide construct 20 to
serve as a negative control, which should not bind to the
available MAbs HC84.1 and V3.2.
Synthesis of the Epitope Mimics for Surface Con-
jugation. Reaction of the thus-synthesized precursor peptides
with either linker construct 7 or 8 led to cyclic peptide
constructs 15, 17, 19, and 20 and linear peptide constructs 16
and 18, respectively (Scheme 2).
This alkylation procedure is convenient since it can be
carried out using the crude, fully deprotected peptides. If the
peptides exhibit good water solubility then normally
NH4HCO3 in a mixture water/acetonitrile can be used.
However, since our peptides were much more hydrophobic,
dimethylformamide (DMF) had to be included for dissolving
the peptides and the alkylation approach was optimized to
dissolve the peptide and the linker in a concentration of 1 mM
in aqueous NH4HCO3 buﬀer (20 mM; pH 7.9) in DMF (75%).
Immediately after alkylation of the peptide on the linker, the
trityl group was removed to liberate the thiol functionality.
Puriﬁcation of the epitope mimics was achieved by
preparative reverse phase HPLC. The TEG spacer improved
the aqueous solubility of the cyclic epitope mimics (15, 17, 19,
and 20), slightly. The linear epitope mimics (16 and 18)
showed a signiﬁcantly better solubility upon attachment of the
TEG containing linker. Nevertheless, all epitope mimics were
Scheme 1. Synthesis of PEG-Based Thiol Linkers for
Peptides Cyclization/Attachment and Conjugation to Plates
Table 1. Overview of the Synthesized Peptidic Antigen Sequences Based on Epitope II of HCV E2 Glycoproteina
acp: cyclization precursor peptide, lp: linear precursor peptide. The cp-sequences have a N- and C-terminal cysteine residue for cyclization whereas
the lp sequences have just one C-terminal residue for attachment to the spacer. Peptide 14 has the scrambled sequence for preparation of the
negative control 20.
Scheme 2. Alkylation of Precursor Peptides with the Linker
Constructs 7 or 8
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obtained in reasonable purity and yields, ranging between 90%
and 95% purity overall with 4−17% yield for the cyclic peptide
constructs 15, 17, 19, and 20 and 4−30% yield for the linear
peptide constructs 16 and 18. In our group, Van de
Langemheen et al. recently developed polar hinges that may
be used for future improvement of the general solubility of
more hydrophobic peptides in cyclization reactions.34
Immobilization by Surface Conjugation to Immobi-
lized Maleimide Residues. To improve conventional ELISA,
the individual epitope mimics were covalently ligated onto
maleimide-activated plates. To verify antibody recognition of
the cyclic epitope mimics (15, 17, and 20) coated plate surface,
plates were incubated with a 3-fold dilution series of MAbs
HC84.1 and V3.2. It was observed that binding of mAb HC84.1
was speciﬁc toward 15 (Figure 3A) and binding of mAb V3.2
was speciﬁc toward 17 (Figure 3B). As expected, the negative
control containing a scrambled peptide sequence (20) did not
bind either mAb HC84.1 or V3.2. As mentioned before, cyclic
epitope mimics 15 and 17 are both based on the epitope II
region. However, the two MAbs HC84.1 and V3.2 bind epitope
II via diﬀerent residues. Therefore, by using the diﬀerent
synthetic peptides 9 (cp) or 11 (cp) it is possible to
demonstrate selectivity of the MAbs toward their respective
cyclic epitope mimics 15 and 17 (Figure 3).
Impact of Peptide Cyclization For Adequate Mimicry
of E2 Peptide Loops. To understand the impact of
cyclization in mimicry of epitopes, we studied the binding of
MAbs HC84.1 and V3.2 to cyclic and linear epitope mimics. To
this end, the cyclic (15 and 17) and linear (16 and 18) epitopes
mimics were ligated separately on maleimide-activated plates.
The covalently ligated surfaces were incubated with a 3-fold
dilution series of MAbs HC84.1 and V3.2. A signiﬁcant
diﬀerence in antibody binding was observed between the
immobilized cyclic and linear epitope mimics, for both MAbs
HC84.1 and V3.2 (Figure 4). mAb HC84.1 successfully bound
cyclic epitope mimic 15, but did not show any binding to the
Figure 3. ELISA comparing the immobilized cyclic epitope mimics 15 and 17 with the immobilized cyclic scrambled epitope 20 using MAbs HC84.1
and V3.2. (A) mAb HC84.1 (3-fold dilution over 7 steps [111.1−0.2 ng/mL]); (B) mAb V3.2 (3-fold dilution over 7 steps [37.0−0.1 ng/mL]).
Background signal (no mAb) was subtracted. The data is represented as a percentage relative to the highest absorbance being set to 100% per
individual experiment (A: 15; B: 17). Data was collected from 3 to 5 independent experiments, each performed in duplicate. Error bars represent the
standard deviation.
Figure 4. ELISA evaluating the eﬀect of cyclization by comparing the immobilized cyclic peptides 15 and 17 with the corresponding linear epitope
mimics 16 and 18 using MAbs HC84.1 and V3.2. (A) mAb HC84.1 (3-fold dilution over by 7 steps [111.1−0.2 ng/mL]); (B) mAb V3.2 (3-fold
dilution over 7 steps [111.1−0.2 ng/mL]). Background signal (no mAb) was subtracted. The data is represented as a percentage relative to the
highest absorbance being set to 100% per individual experiment (A: 15; B: 17). Data was collected from 3 independent experiments, each performed
in duplicate. Error bars represent the standard deviation.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.7b00755
Bioconjugate Chem. 2018, 29, 1091−1101
1094
corresponding linear epitope mimic 16 (Figure 4A). In
addition, mAb V3.2 was capable of binding cyclic epitope
mimic 17 but showed almost no binding to the corresponding
linear epitope mimic 18 (Figure 4B). These results strongly
emphasize the importance of peptide cyclization for antibody
recognition, which in turn advocates peptide cyclization for
accurate mimicry of epitopes. The diﬀerence between mAb
HC84.1 not binding linear epitope mimic 16 at all and mAb
V3.2 binding linear epitope mimic 18 to a minor extent
suggests that the importance of peptide cyclization could be
sequence dependent. Perhaps, certain linear peptides readily
resemble the conformation of cyclized peptides.
Cyclization of our peptide sequence resulted in epitope
mimics that exhibit a higher aﬃnity toward antibodies. This
serves as direct evidence that conformational constraints in
peptides resulted in improved mimicry. Nevertheless, the
ﬂexibility of linear peptides might allow certain conformations
to mold themselves onto binding interfaces, similar to a lock
and key model. Krey et al. have successfully cocrystallized
human mAb HC84.1 bound to a linear peptide based on the
Epitope II region of HCV E2.10 The human mAb HC84.1 has
been shown to bind the peptide in a α-helical conformation.
Perhaps, the linear peptide has adopted partially an α-helix in
solution or an α-helix was induced upon binding to HC84.1. In
this work, the linear epitope mimic 16 showed a major
detrimental eﬀect on binding mAb HC84.1, which could
indicate the inability of linear precursor peptide 10 (lp) to form
a necessary α-helical structure while alkylated on the linker.
However, binding of mAb HC84.1 was achieved by
immobilized cyclic epitope mimic 15, which suggests that the
required interacting conformation of the ﬂexible linear peptide
might be enforced by cyclization. Since epitope mimicry is
based on individual peptide sequences of proteins being grafted
on molecular scaﬀolds, it is inevitable that the intrinsically
adopted conformations of linear peptides will be inﬂuenced.
Therefore, conformational constraints are necessary to
preorganize the peptides into the required conformations.
Nevertheless, it is not assumed that our cyclized peptides
behave similarly to stapled peptides in which the α-helix
character is enhanced by side chain cyclization, since stapling
usually involves cyclization by Ring Closing Metathesis (RCM)
of (disubstituted) amino acid residues i and i+4 or residues i
and i+7. In peptide 15 side chains of residues i and i+14 are
connected.
Employing Epitope Mimic Coated Surfaces for
Identiﬁcation of Key Binding Residues. Since cyclic
peptide precursor 11 (cp) is elongated at the N-terminus
compared to peptide cyclic peptide precursor 9 (cp), some
degree of cross-reactivity of MAbs HC84.1 and V3.2 was
expected toward both cyclic epitope mimics 15 and 17.
However, no such cross-reactivity was observed at the antibody
concentrations used. Interestingly, residues involved in binding
mAb HC84.1 (437W, 441L, 442F, 443Y)9 or mAb V3.2 might
diﬀer. Typically, mutagenesis studies are used to identify key
binding residues within epitopes involved in antibody
recognition. For these, several recombinant mutants of E2
have to be generated that are screened in ELISA to evaluate the
altered binding aﬃnity of the antibodies. The process of
generating a multitude of diﬀerent recombinant E2 sequences is
a rather laborious and time-consuming process. Instead, epitope
mimics could be used as a more high-throughput screening
method as collections of synthetic peptides can be easily
obtained in a fast and automated fashion. Subsequently, the
diﬀerent synthetic peptides can be conveniently cyclized on
linker 7, conjugated on maleimide-activated plates, and
analyzed using ELISA.
In order to evaluate whether cyclic epitope mimics could be
used similar to high-throughput mutagenesis studies for
identiﬁcation of key binding residues, it was decided to try to
identify those involved in binding mAb V3.2. The major
diﬀerence in the overlapping peptide sequence between cyclic
precursor peptides 9 (cp) and 11 (cp) is a Valine-to-Leucine
change at position 438. To this end, a mutant cyclic precursor
peptide 13 (cp) was synthesized that contained a Valine-to-
Leucine change on position 438 (V438L). Cyclic precursor
peptide 13 (cp) was subsequently cyclized to prepare cyclic
epitope mimic 19, which was then conjugated on maleimide-
activated plates, and tested using ELISA. Monoclonal antibod-
Figure 5. ELISA showing the relative importance of diﬀerent immobilized cyclic epitope mimics 15, 17, and 19 toward binding of MAbs HC84.1
and V3.2. (A) mAb HC84.1 (3-fold dilution over 6 steps [37.0−0.2 ng/mL]); (B) mAb V3.2 (3-fold dilution over 5 steps [37.0−0.5 ng/mL]).
Background signal (no mAb) was subtracted. The data is represented as a percentage relative to the highest absorbance being set to 100% per
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ies HC84.1 and V3.2 were tested against plate surfaces
containing immobilized cyclic epitope mimics (15, 17, or
19). The cyclic epitope mimic 15 showed good binding of mAb
HC84.1 (Figure 5A) but no binding of mAb V3.2. In contrast,
cyclic epitope mimic 17 showed good binding of mAb V3.2
(Figure 5B). Valine-to-Leucine change containing cyclic
epitope mimic 19 showed a small decrease in binding by
mAb HC84.1 (Figure 5A), but showed improved binding by
mAb V3.2 (Figure 5B). This result suggested that the leucine
sequence at position 438 is crucial for binding mAb V3.2.
■ CONCLUSION
In conclusion, we have synthesized epitope mimics containing
peptides based on Epitope II of the HCV E2 glycoprotein using
benzyl bis and mono bromide derivatives functionalized with a
ﬂexible TEG spacer equipped with a thiol-moiety. The thiol-
moiety enabled chemoselective covalent coating of epitope
mimics to a maleimide-activated surface. As a result uniform
peptide layers were obtained on a solid surface, for which we
hypothesized that the epitope structure is better preserved than
when peptides are noncovalently absorbed onto the ELISA
plates. In addition, covalent adsorption prevents a gradual
leakage of peptides from the surface. The epitope mimics
peptide sequences originated from HCV E2 and were
presented as both cyclic and linear peptides, allowing
investigation of the necessity of conformationally constraining
of peptide sequences for optimal epitope mimicry.
The broadly neutralizing antibody HC84.1 and weakly
neutralizing antibody V3.2 that target epitope II of HCV E2,
successfully recognized the immobilized cyclic epitope mimics.
In addition, it has been shown that cyclization was essential or
at least signiﬁcantly improved recognition of epitope mimics.
Although it is widely assumed that introducing conformational
constraints for example by cyclization in (synthetic) peptides
for eﬀective mimicry of epitopes is crucial or at least beneﬁcial
for recognition by antibodies, to the best of our knowledge, this
is the ﬁrst time that this has been demonstrated in a convincing
molecular experimental approach.
Thus, we do not pretend that our cyclization method will
favor or stabilize a particular secondary structure, but rather will
provide a more stable mimic of the spatial structure of the
peptide segment in thein this caseviral envelope protein
than is the case when using a linear peptide.
The novel ELISA platform that has been developed here
provides an easy, straightforward, and reliable strategy for
cyclization of peptides and subsequent conjugation of these
cyclic peptides covalently to an ELISA plate. This opens up
possibilities for studying antibody−epitope interaction in a
high-throughput fashion and might be an attractive tool in
vaccine design.
Finally, the use of synthetically modiﬁed epitope peptides in
which amino acids are replaced instead of using the entire
recombinantly mutated proteins for studying the relative
binding aﬃnity by antibodies employing this approach is also
a particularly promising perspective.
■ EXPERIMENTAL SECTION
General Procedures. All reagents and solvents were used
as received. Fmoc-amino acids were obtained from Activotec
(Cambridge, United Kingdom) and N,N,N′,N′-Tetramethyl-O-
(6-chloro-1H-benzotriazol-1-yl)uranium hexaﬂuorophosphate
(HCTU) was obtained from Matrix Innovation (Quebec,
Canada). Tentagel S RAM resin (particle size 90 μm, capacity
0.25 mmol.g−1) was obtained from IRIS Biotech (Marktred-
witz, Germany). Methyl tert-butyl ether (MTBE), hexane
(HPLC grade), and TFA were obtained from Aldrich
(Milwaukee, USA). DMF (Peptide grade) was obtained from
VWR (Lutterworth, United Kingdom). Piperidine and DiPEA
were obtained from AGTC Bioproducts (Hessle, United
Kingdom) and 1,2-ethanedithiol (EDT) was obtained from
Merck (Darmstadt, Germany). HPLC grade CH2Cl2 and
acetonitrile were obtained from Fischer Scientiﬁc (Lough-
borough, United Kingdom). Solid phase peptide synthesis was
performed on a PTI Tribute-UV peptide synthesizer.
Lyophilizations were performed on a Christ Alpha 2−4 LDplus
apparatus. Reactions were carried out at ambient temperature
unless stated otherwise. Solvents were evaporated under
reduced pressure at 40 °C. Reactions in solution were
monitored by TLC analysis and Rf values were determined
on Merck precoated silica gel 60 F-254 (0.25 mm) plates. Spots
were visualized by UV-light and permanganate stain. Column
chromatography was performed on Siliaﬂash P60 (40−63 μm)
from Silicycle (Canada) or on a Biotage Isolera One
puriﬁcation system using prepacked silica (KP-SIL) Biotage
SNAP cartridges. 1H NMR data was acquired on a Bruker 400
MHz spectrometer in CDCl3 as solvent. Chemical shifts (δ) are
reported in parts per million (ppm) relative to trimethylsilane
(TMS, 0.00 ppm). Analytical high-pressure liquid chromatog-
raphy (HPLC) was carried out on a Shimadzu instrument
comprising a communication module (CBM-20A), autosam-
pler (SIL-20HT), pump modules (LC-20AT), UV/vis detector
(SPD-20A), and system controller (Labsolutions V5.54 SP),
with a Phenomenex Gemini C18 column (110 Å, 5 μm, 250 ×
4.60 mm) or Dr. Maisch Reprosil Gold 200 C18 (5 μm, 250 ×
4.60 mm). UV measurements were recorded at 214 and 254
nm, using a standard protocol: 100% buﬀer A (acetonitrile/
H2O 5:95 with 0.1% TFA) for 2 min followed by a linear
gradient of buﬀer B (acetonitrile/H2O 95:5 with 0.1% TFA)
into buﬀer A (0−100% or 0−50%) over 30 min at a ﬂow rate of
1.0 mL·min−1. Puriﬁcation of the peptidic compounds was
performed on an Agilent Technologies 1260 inﬁnity preparative
system using both UV and ELSD detectors with a Phenomenex
Gemini C18 column (110 Å, 10 μm, 250 × 20 mm) or Dr.
Maisch Reprosil Gold 200 C18 (10 μm, 250 × 20 mm).
Autocollection of fractions was used based on the UV
measurements at 214 nm, using a standard protocol: 80%
buﬀer A for 5 min followed by a linear gradient of buﬀer B into
buﬀer A (0−50% or 20−60%) over 60 min at a ﬂow rate of
12.5 mL·min−1 using the same buﬀers as described for the
analytical HPLC. Liquid chromatography mass spectrometry
(LCMS) was carried out on a Thermo Scientiﬁc LCQ Fleet
quadrupole mass spectrometer with a Dionex Ultimate 3000
LC using a Dr. Maisch Reprosil Gold 120 C18 column (110 Å,
3 μm, 150 × 4.0 mm) and the same linear gradients of buﬀer B
into buﬀer A, ﬂow rate and buﬀers as described for the
analytical HPLC.
General Method for Automated Peptide Synthesis.
The peptides were synthesized on a PTI Tribute-UV peptide
synthesizer. Tentagel S RAM resin (1.0 g, 0.25 mmol, 1.0 equiv
or 400 mg, 0.1 mmol, 1.0 equiv) was allowed to swell in DMF
(3 × 10 min). Deprotection of the Fmoc group was achieved by
treatment of the resin with 20% piperidine in DMF using the
RV_top_UV_Xtend protocol from the Tribute-UV peptide
synthesizer followed by a DMF washing step (5 × 30 s). The
Fmoc-protected amino acids were coupled using HCTU (with
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the 0.1 mmol scale 5 equiv was used and with the 0.25 mmol
scale 4 equiv was used) and DiPEA (with the 0.1 mmol scale 10
equiv was used and with the 0.25 mmol scale 8 equiv was used)
in DMF, as a coupling system, with 2 min preactivation. The
coupling time was 10 min when the peptide was synthesized on
a 0.1 mmol scale and 20 min when the 0.25 mmol scale was
conducted. After every coupling the resin was washed with
DMF (6 × 30 s). After coupling of the last amino acid, the
Fmoc group was cleaved using the normal deprotection
conditions (described above) and the resulting free N-terminus
was acetylated by treating the resin bounded peptide with acetic
anhydride (250 μL) and DiPEA (10 equiv for the 0.1 mmol
scale and 8 equiv for the 0.25 mmol scale) in DMF using the
standard coupling times (described above). In the last step the
resin was washed with DMF (5 × 30 s), DCM (5 × 30 s), and
dried over a nitrogen ﬂow for 10 min, followed by the cleavage
of the resin-bounded peptide. Cleavage and deprotection was
achieved by treatment of the resin with TFA/H2O/TIS/EDT
(15 mL for the 0.25 mmol scale and 5 mL for the 0.1 mmol
scale, 90:5:2.5:2.5, v/v/v/v) for 3 h at rt. The peptide was
precipitated in MTBE/hexane (1:1, 90 mL for the 0.25 mmol
scale and 45 mL for the 0.1 mmol scale), centrifuged, the
supernatant decanted and the pellet washed 5 times with
MTBE/hexane (1:1, 45 mL). The resulting pellet was
redissolved in t-BuOH/H2O (1:1, v/v) and lyophilized.
General Method for Peptide Alkylation. Crude
precursor peptide (25 μmol; 1.0 equiv) was dissolved in
DMF (18 mL). Subsequently, a solution of cyclization (7) or
linear (8) linker (37.5 μmol; 1.5 equiv) in DMF (1 mL) was
added. Subsequently, an aqueous NH4HCO3 buﬀer solution
(pH 7.9, 20 mM; 6 mL) was added dropwise to the reaction
mixture, which gave a general peptide concentration of ≤1 mM
in DMF/buﬀer solution (3:1, v/v). The reaction mixture was
stirred for 2 h at room temperature, followed by concentration
in vacuo. The residue was redissolved in TFA/H2O/TIS/EDT
(15 mL, 90:5:2.5:2.5, v/v/v/v) and the resulting reaction
mixture was stirred for 3 h at room temperature. Then, the
crude product was precipitated in 2 × 50 mL MTBE/hexane
(1:1, v/v). The crude precipitate was obtained by centrifugation
(4500 rpm, 5 min). The collected precipitate was washed an
additional four times using 2 × 50 mL MTBE/hexane (1:1, v/
v) and centrifugation (4500 rpm, 5 min). After this the crude
product was dissolved in tBuOH/H2O (1:1, v/v) and
lyophilized.
Monoclonal Antibodies. The human−mouse chimeric
antibody cHC84.1 was generated by grafting the nucleotide
sequences encoding the variable heavy and variable light chain
of human mAb HC84.1 (10) on the mouse IgG1 backbone.
The resulting chimeric antibody was expressed in HEK-293T
cells and puriﬁed using protein-G aﬃnity chromatography. The
mouse mAb V3.2 was generated by immunizing mice with
recombinant virus-like particles of HCV. Like HC84.1, the
epitope of V3.2 recognizes amino acid residues within the
epitope II region of HCV E2 glycoprotein. A detailed
characterization of this antibody will be reported elsewhere.
General Method for ELISA. Pierce maleimide activated 96-
well plates were purchased from Thermo Scientiﬁc. The wells
were washed three times with 200 μL wash buﬀer (0.1 M
Na3PO4, 0.15 M NaCl, 0.05% Tween-20 detergent; pH 7.2).
Then, the desired epitope mimic (100−500 μg) was suspended
in 1 mL binding buﬀer (0.1 M Na3PO4, 0.15 M NaCl, 10 mM
EDTA; pH 7.2) and further diluted (10−50 fold) to a
concentration of 10 μg/mL. To each well, 200 μL of the
epitope mimic solution was added and incubated overnight at 4
°C. After this, the wells were washed three times with 200 μL
wash buﬀer. For capping unreacted maleimide groups,
immediately before use, a solution of 10 μg/mL N-acetylated
cysteine was prepared and 200 μL was added to each of the
wells, followed by incubation for 1−2 h at room temperature.
Then, the wells were washed three times with 200 μL wash
buﬀer. A 3-fold dilution series of primary mAb was prepared in
wash buﬀer and 100 μL was transferred to each well, followed
by incubation for 1−2 h at room temperature. After this, the
wells were washed three times with PBST, before supplying 100
μL 1:2000 secondary HRP-conjugated α-mouse A4416
(Sigma) antibodies in wash buﬀer to each well. Incubation
continued for 1−2 h at room temperature, followed by washing
the wells three times with PBST. The plates were developed
using 100 μL 3,3′,5,5′ tetramethylbenzidine (TMB) solution
per well, obtained from Life Technologies, and incubating for
25 min at room temperature, after which, further development
was stopped using 200 μL 0.5 M H2SO4 per well. Absorbance
at 450 nm was measured on a Varioskan (Thermoscientiﬁc) or
PHERAstar FS (BMG Labtech) instrument.
Tetraethylene Glycol p-Toluenesulfonate (2). All steps
were carried out under N2 atmosphere. Commercially available
TEG 1 (8.6 mL, 50.0 mmol, 2.0 equiv) was dissolved in dry
CH2Cl2 (100 mL). The resulting solution was cooled to 0 °C
using an ice bath, followed by addition of TEA (7.0 mL, 50.0
mmol, 2.0 equiv). After 1h p-toluenesulfonyl chloride (4.8 g, 25
mmol, 1.0 equiv) was added, the ice bath was removed, and the
resulting reaction mixture was stirred for 16 h at room
temperature. Next, the reaction mixture was washed with 1 M
HCl (aq) (2 × 100 mL) and H2O (100 mL). The obtained
aqueous layers were combined and back-extracted with CH2Cl2
(100 mL). All CH2Cl2 layers were combined and washed with
brine (200 mL) and dried over Na2SO4, followed by ﬁltration.
The ﬁltrate was concentrated in vacuo, aﬀording the crude
product as a yellowish syrup. Puriﬁcation by automated ﬂash
column chromatography (100% EtOAc) aﬀorded tetraethylene
glycol p-toluenesulfonate (2) (5.4 g, 15.4 mmol, 61%) as a clear
yellowish syrup. Rf = 0.45 (EtOAc); tR = 25.0 min;
1H NMR
(400 MHz, CDCl3): δ = 7.79 (d,
3JHH = 8.2 Hz, 2H, aryl-H),
7.34 (m, 3JHH = 8.2 Hz, 2H, aryl-H), 4.16 (m,
3JHH = 4.8 Hz,
2H, TosOCH2), 3.70 (m, 4H, 2 × CH2), 3.64 (m, 2H, 4 ×
CH2), 3.60 (m, 6H, 3 × CH2), 2.44 (s, 3H, CH3) 2.35 (broad s,
1H, OH) ppm; 13C NMR (101 MHz, CDCl3): 144.8 (aryl-C),
133.1 (aryl-C), 129.8 (m-aryl-CH), 128.0 (o-aryl-CH), 72.5
(CH2), 70.8 (CH2), 70.7 (CH2), 70.5 (CH2), 70.4 (CH2), 69.2
(TosOCH2), 68.7 (CH2), 61.8 (CH2), 21.64 (CH3); HRMS:
calculated m/z for C15H24NaO7S: 371.1135 [M+Na]
+1; found
371.1128.
Triphenylmethanethiol (3). All steps were carried out
under N2 atmosphere. Commercially available trityl chloride
(13.9 g, 50.0 mmol, 1.0 equiv) was dissolved in acetone (200
mL). The resulting solution was added to a vigorously stirring
solution of NaSH.H2O (11.3 g, 201.2 mmol, 4.0 equiv) in
acetone/H2O 1:1, v/v (400 mL). The resulting reaction
mixture was stirred at room temperature for 15 min. Then,
additional H2O (200 mL) was added to the reaction mixture
and stirring was continued for 1 h. The crude product
precipitated as a yellow solid, which was ﬁltered and was
washed thoroughly with H2O. The resulting yellow solid was
dried in vacuo, aﬀording 11.1 g (40.0 mmol, 80%) crude
triphenylmethanethiol (3), which was used without additional
puriﬁcation. Rf = 0.85 (EtOAc/Petroleum Ether 40−60 °C 1:9,
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v/v); tR = 45.6 min;
1H NMR (400 MHz, CDCl3): δ = 7.26 (m,
15H, aryl-H), 3.08 (s, 1H, SH) ppm; 13C NMR (101 MHz,
CDCl3): δ = 147.2 (aryl-C), 129.3 (aryl-CH), 127.8 (aryl-CH),
126.9 (aryl-CH), 62.9 (CS) ppm. HRMS: calculated m/z for
C19H15S: 275.0900 [M-H]
−; found 275.0892.
Tetraethylene Glycol Monotrityl Thioether (4). All
steps were performed under N2 atmosphere. Crude triphe-
nylmethylthiol 3 (11.1 g, 40.0 mmol, 2.6 equiv) was dissolved
in dry THF (100 mL). The resulting solution was cooled to 0
°C using an ice bath, followed by addition of 1.6 g NaH (60%
in mineral oil; 40.0 mmol, 2.6 equiv). The resulting suspension
was stirred for 1 h at 0 °C. A separate solution of tetraethylene
glycol p-toluenesulfonate 2 (5.4 g, 15.4 mmol, 1.0 equiv) was
prepared in dry THF (10 mL), which was added to the reaction
mixture at 0 °C. After this, the ice bath was removed and the
reaction mixture was stirred for another 15−30 min at room
temperature. Upon completion of the reaction, as determined
by TLC (EtOAc), the reaction mixture was quenched by
addition of a sat. NH4Cl (aq) (100 mL) solution while
vigorously stirring for an additional 15 min. Then, THF was
removed in vacuo and EtOAc (100 mL) was added. The
aqueous and organic layers were separated. The EtOAc layer
was washed with H2O (2 × 100 mL). The combined aqueous
layers were back-extracted with EtOAc (100 mL). The obtained
organic layers were combined and washed with brine (200 mL),
dried over Na2SO4, and ﬁltered. The ﬁltrate was concentrated
in vacuo, which aﬀorded the crude product as a yellow oil.
Puriﬁcation was immediately performed by automated ﬂash
column chromatography (100% EtOAc) aﬀorded tetraethylene
glycol monotrityl thioether (4) (6.9 g, 15.2 mmol, quant.) as a
yellow oil. Rf = 0.59 (EtOAc); tR = 39.1 min;
1H NMR (400
MHz, CDCl3): δ = 7.42 (m, 6H, trityl o-H), 7.28 (m, 6H, trityl
m-H), 7.21 (m, 3H, p-H), 3.70 (m, 2H, CH2OH), 3.64 (m, 4H,
CH2), 3.58 (m, 4H, CH2), 3.45 (m, 2H, CH2), 3.30 (t,
3JHH =
6.9 Hz, 2H, SCH2CH2O), 2.44 (t,
3JHH = 6.9 Hz, 2H, SCH2),
2.34 (broad s, 1H, OH) ppm; 13C NMR (101 MHz, CDCl3): δ
= 144.8 (Ar-C), 129.6 (o-Ar-CH), 127.9 (m-Ar-CH), 126.6 (p-
Ar-CH), 72.5 (CH2), 70.7 (CH2), 70.5 (CH2), 70.4 (CH2), 70.2
(CH2), 69.7 (SCH2CH2O), 66.6 (SC), 61.8 (CH2), 31.7
(SCH2); HRMS: calculated m/z for C27H32NaO4S: 475.1914
[M+Na]+1; found 475.1900.
Benzylic Bromide Linkers. All steps were carried out
under N2 atmosphere. Tetraethylene glycol monotrityl
thioether 4 (3.4 g, 7.6 mmol) was dissolved in dry THF (50
mL). The resulting solution was cooled to 0 °C using an ice
bath, followed by the addition of 0.5 g NaH (60% in mineral
oil; 11.4 mmol, 1.5 equiv). After this, the reaction mixture was
stirred for 1 h at 0 °C. Then, tetraethylene glycol monotrityl
thioether 4 was added in portions to a solution of 1,3,5-
tris(bromomethyl)benzene 5 or α,α′-dibromide-m-xylene 6 and
stirring continued for 16 h. Upon completion of the reaction, as
determined by TLC (30% EtOAc in petroleum ether 40−60
°C), THF was removed in vacuo. Then, the residue was
dissolved in EtOAc, followed by ﬁltration over Celite to remove
salts. The ﬁltrate was concentrated in vacuo, which aﬀorded the
crude product. Puriﬁcation by automated ﬂash column
chromatography using a linear gradient (10−30% EtOAc in
petroleum ether 40−60 °C over 20 column volumes) aﬀorded
pure product.
Cyclization Linker (7). 1,3,5-Tris(bromomethyl)benzene 5
(1.5 g, 4.2 mmol, 1.1 equiv) was dissolved in dry THF (75 mL),
followed by the portionwise addition (5 × 5 mL) of the above-
described reaction mixture containing tetraethylene glycol
monotrityl thioether 4 (1.7 g, 3.8 mmol, 1.0 equiv) with 15
min intervals. Puriﬁcation as described above aﬀorded pure
cyclization linker (7) (0.9 g, 1.3 mmol, 33%) as a yellow oil. (Rf
= 0.31 (petroleum ether 40−60 °C/EtOAc 7:3, v/v); tR = 49.1
min; 1H NMR (400 MHz, CDCl3): δ = 7.41 (m, 6H, o-trityl−
CH), 7.32 (m, 1H, p-aryl−CH), 7.29 (m, 2H, o-aryl−CH), 7.27
(m, 6H, m-trityl−CH), 7.21 (m, 3H, p-trityl−CH), 4.53 (s, 2H,
OCH2-aryl), 4.45 (s, 4H, 2 × CH2Br), 3.66 (m, 8H, 4 × CH2),
3.58 (m, 2H, CH2), 3.45 (m, 2H, CH2), 3.30 (t,
3JHH = 6.9 Hz,
2H, SCH2CH2), 2.43(t,
3JHH = 6.9 Hz, 2H, SCH2) ppm;
13C
NMR (101 MHz, CDCl3): δ = 144.8 (trityl-C), 139.9 (aryl-
C(CH)2), 138.5 (aryl-C(CH2Br)2), 129.6 (o-trityl-CH), 128.8
(aryl-CH(CCH2Br)2), 128.1 (o-aryl-CH), 127.9 (m-trityl-CH),
126.6 (p-trityl-CH), 72.5 (OCH2-aryl), 70.7 (2 × CH2), 70.6
(CH2), 70.5 (CH2), 70.2 (CH2), 69.9 (CH2), 69.6 (SCH2CH2),





Linear Linker (8). α,α′-Dibromide-m-xylene 6 (1.1 g, 4.2
mmol, 1.1 equiv) was dissolved in dry THF (75 mL), followed
by the portionwise addition (5 × 5 mL) of the above-described
reaction mixture containing tetraethylene glycol monotrityl
thioether 4 (1.7 g, 3.8 mmol, 1.0 equiv) with 15 min intervals.
Puriﬁcation as described above aﬀorded pure cyclization linker
(8) (1.0 g, 1.6 mmol, 43%) as a yellow oil Rf = 0.36 (petroleum
ether 40−60 °C/EtOAc 7:3, v/v); tR = 48.3 min; 1H NMR
(400 MHz, CDCl3): δ = 7.41 (m, 6H, o-trityl−CH), 7.37 (m,
1H, p-aryl−CH), 7.30 (m, 3H, o-aryl−CH), 7.27 (m, 6H, m-
trityl−CH), 7.21 (m, 3H, p-trityl−CH), 4.54 (s, 2H, OCH2-
aryl), 4.48 (s, 4H, 2 × CH2Br), 3.64 (m, 8H, 4 × CH2), 3.57
(m, 2H, CH2), 3.45 (m, 2H, CH2), 3.30 (t,
3JHH = 6.9 Hz, 2H,
SCH2CH2), 2.42 = (t,
3JHH = 6.9 Hz, 2H, SCH2) ppm;
13C
NMR (101 MHz, CDCl3): δ = 144.8 (trityl-C), 139.1 (aryl-
C(CH)2), 137.9 (aryl-CCH2Br), 129.6 (o-trityl-CH), 128.8
(aryl-CCH(CCH2Br)), 128.2 (aryl-CH), 127.9 (m-trityl-CH),
127.7 (aryl-CH), 126.6 (p-trityl-CH), 72.8 (OCH2-aryl), 70.7
(3 × CH2), 70.5 (CH2), 70.2 (CH2), 69.7 (CH2), 69.6
(SCH2CH2), 66.6 (CS), 33.4 (CH2Br), 31.7 (SCH2) ppm;
HRMS: calculated m/z for C35H39NaO4S
79Br: 657.1645 [M
+Na]+1; found 657.1629.
Cyclic Precursor Peptide 9 (cp). The peptide was
synthesized as described above by solid phase synthesis on a
0.25 mmol scale, which aﬀorded crude peptide (397.9 mg).
This crude peptide was used in the cyclization by alkylation
step. tR = 19.2 min; LRMS: m/z calculated for
C89H117N21O19S2: 924.92 1/2[M+2H]
2+; found: 925.33 (13C
[+1]).
Linear Precursor Peptide 10 (lp). The peptide was
synthesized as described above by solid phase synthesis on a
0.25 mmol scale, which aﬀorded crude peptide (433.5 mg).
This crude peptide was used in the alkylation step. tR = 18.9
min; LRMS: m/z calculated for C86H112N20O18S: 873.42 1/
2[M+2H]2+; found: 873.92 (13C [+1]).
Cyclic Precursor Peptide 11 (cp). The peptide was
synthesized as described above by solid phase synthesis on a
0.25 mmol scale, which aﬀorded crude peptide (322.3 mg).
This crude peptide was used in the cyclization by alkylation
step. tR = 21.7 min; m/z calculated for C91H127N21O26S2:
997.94 1/2[M+2H]2+; found: 998.08 (13C [+1]).
Linear Precursor Peptide 12 (lp). The peptide was
synthesized as described above by solid phase synthesis on a
0.25 mmol scale, which aﬀorded crude peptide (390.5 mg).
This crude peptide was used in the alkylation step. tR = 21.5
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min; m/z calculated for C88H122N20O25S: 946.44 1/2[M
+2H]2+; found: 946.75 (13C [+1]).
Cyclic Precursor Peptide 13 (cp). The peptide was
synthesized as described above by solid phase synthesis on a
0.25 mmol scale, which aﬀorded crude peptide (382.7 mg).
This crude peptide was used in the cyclization by alkylation
step. tR = 19.7 min; m/z calculated for C90H119N21O19S2:
931.93 1/2[M+2H]2+; found: 932.33.
Cyclic Precursor Peptide 14 (cp). The peptide was
synthesized as described above by solid phase synthesis on a
0.25 mmol scale, which aﬀorded crude peptide (332.3 mg).
This crude peptide was used in the cyclization by alkylation
step. tR = 19.1 min; m/z calculated for C90H119N21O19S2:
931.93 1/2[M+2H]2+; found: 932.50 (13C [+1]).
Cyclic Epitope Mimic 15. Crude cyclic precursor 9 (cp)
(46.2 mg, 25 μmol, 1.0 equiv) was treated with cyclization
linker 7 (27.3 mg, 38 μmol, 1.5 equiv) according to the general
method for peptide alkylation as described above. The obtained
crude product (53.9 mg) was dissolved in HPLC buﬀers A and
B (1:1, v/v) as three batches of 10−20 mg in 3 mL. Each batch
was puriﬁed by preparative HPLC using a linear gradient of
HPLC buﬀer B in HPLC buﬀer A (0−50%; 60 min). Fractions
containing pure product were combined and lyophilized to
yield pure cyclic epitope mimic 15 (9.7 mg, 15.4% overall yield;
95% average yield per step) as a ﬂuﬀy white powder. tR = 21.6
min; LRMS: calculated m/z for C106H141N21O23S3: 1087.00 1/
2[M+2H]+2; found 1087.50 (13C [+1]); HRMS: calculated m/z
for C106H141N21O23S3: 1086.9914 1/2[M+2H]
+2; found
1086.9400.
Linear Epitope Mimic 16. Crude linear precursor 10 (lp)
(66.4 mg, 38 μmol, 1.0 equiv) was treated with linear linker 8
(35.9 mg, 57 μmol, 1.5 equiv) according to the general method
for peptide alkylation as described above. The obtained crude
product (67.8 mg) was dissolved in HPLC buﬀers A and B
(1:1, v/v) as two batches of 20−40 mg in 2−5 mL. Each batch
was puriﬁed by preparative HPLC using a linear gradient of
HPLC buﬀer B in HPLC buﬀer A (0−50%; 60 min). Fractions
containing pure product were combined and lyophilized to
yield pure linear epitope mimic 16 (23.1 mg, 29.3% overall
yield; 96% average yield per step) as a ﬂuﬀy white powder. tR =
22.1 min; LRMS: calculated m/z for C102H136N20O22S2:
1029.49 1/2[M+2H]+2; found 1030.00 (13C [+1]); HRMS:
calculated m/z for C102H136N20O22S2: 1029.4868 1/2[M
+2H]+2; found 1029.4826.
Cyclic Epitope Mimic 17. Crude cyclic precursor 11 (cp)
(50.5 mg, 25 μmol, 1.0 equiv) was treated with cyclization
linker 7 (27.7 mg, 38 μmol, 1.5 equiv) according to the general
method for peptide alkylation as described above. The obtained
crude product (60.7 mg) was dissolved in HPLC buﬀers A and
B (1:1, v/v) as three batches of, respectively, 15−25 mg in 3
mL. Each batch was puriﬁed by preparative HPLC using a
linear gradient of HPLC buﬀer B in HPLC buﬀer A (20−60%;
60 min). Fractions containing pure product were combined and
lyophilized to yield pure cyclic epitope mimic 17 (4.3 mg, 4.7%
overall yield; 93% average yield per step) as a ﬂuﬀy white
powder. tR = 22.6 min; LRMS: calculated m/z for
C108H151N21O30S3: 1160.01 1/2[M+2H]
+2; found 1160.42
(13C [+1]); HRMS: calculated m/z for C108H151N21O30S3:
1157.9971 1/2[M-2H]+2; found 1157.9971.
Linear Epitope Mimic 18. Crude linear precursor 12 (lp)
(72.6 mg, 38 μmol, 1.0 equiv) was treated with linear linker 8
(35.9 mg, 57 μmol, 1.5 equiv) according to the general method
for peptide alkylation as described above. The obtained crude
product (77.6 mg) was dissolved in HPLC buﬀers A and B
(1:1, v/v) as two batches of 20−30 mg in 2−3 mL. Each batch
was puriﬁed by preparative HPLC using a linear gradient of
HPLC buﬀer B in HPLC buﬀer A (20−60%; 60 min).
Fractions containing pure product were combined and
lyophilized to yield pure linear epitope mimic 18 (3.5 mg,
3.4% overall yield; 91% average yield per step) as a ﬂuﬀy white
powder. tR = 23.6 min; LRMS: calculated m/z for
C104H146N20O29S2: 1102.51 1/2[M+2H]
+2; found 1102.75
(13C [+1]). HRMS: calculated m/z for C104H146N20O29S2:
1102.5082 1/2[M+2H]+2; not found (no ionization).
Cyclic Epitope Mimic 19. Crude cyclic precursor 13 (cp)
(46.4 mg, 25 μmol, 1.0 equiv) was treated with cyclization
linker 7 (27.3 mg, 38 μmol, 1.5 equiv) according to the general
method for peptide alkylation as described above. The obtained
crude product (51.2 mg) was dissolved in HPLC buﬀers A and
B (1:1, v/v) as three batches of 10−20 mg in 2−3 mL. Each
batch was puriﬁed by preparative HPLC using a linear gradient
of HPLC buﬀer B in HPLC buﬀer A (0−50%; 60 min).
Fractions containing pure product were combined and
lyophilized to yield pure cyclic epitope mimic 19 (4.9 mg,
7.4% overall yield; 93% average yield per step) as a ﬂuﬀy white
powder. tR = 22.3 min; LRMS: calculated m/z for
C107H143N21O23S3: 1094.00 1/2[M+2H]
+2; found 1094.50
(13C [+1]); HRMS: calculated m/z for C107H143N21O23S3:
1093.9993 1/2[M+2H]+2; found 1093.9941.
Cyclic Epitope Mimic 20. Crude cyclic precursor 14 (cp)
(46.4 mg, 25 μmol, 1.0 equiv) was treated with cyclization
linker 7 (27.3 mg, 38 μmol, 1.5 equiv) according to the general
method for peptide alkylation as described above. The obtained
crude product (50.0 mg) was dissolved in HPLC buﬀers A and
B (1:1, v/v) as three batches of 10−20 mg in 2−3 mL. Each
batch was puriﬁed by preparative HPLC using a linear gradient
of HPLC buﬀer B in HPLC buﬀer A (0−50%; 60 min).
Fractions containing pure product were combined and
lyophilized to yield pure cyclic epitope mimic 20 (6.7 mg,
8.8% overall yield; 93% average yield per step) as a ﬂuﬀy white
powder. tR = 21.8 min; LRMS: calculated m/z for
C107H143N21O23S3: 1094.00 1/2[M+2H]
+2; found 1094.50
(13C [+1]); HRMS: calculated m/z for C107H143N21O23S3:
1093.9992 1/2[M+2H]+2; found 1093.9936.
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